VEGFA and neoplasm: The ramucirumab monoclonal antibody is another antiangiogenic approved for the treatment of locally advanced or metastatic NSCLC, as its targets block the binding of VEGF and VEGFR2, and subsequently inhibit angiogenesis and the migration of the tumor.